Human protein arginine N-methyltransferase 2 (PRMT2, HRMT1L1) is a protein that belongs to the arginine methyltransferase family, and it has diverse roles in transcriptional regulation through different mechanisms depending on its binding partners. In this study, we provide evidences for the negative effect of PRMT2 on breast cancer cell proliferation in vitro and in vivo. Morever, cyclin D1, one of the key modulators of cell cycle, was found to be downregulated by PRMT2, and PRMT2 was further shown to suppress the estrogen receptor a-binding affinity to the activator protein-1 (AP-1) site in cyclin D1 promoter through indirect binding with AP-1 site, resulting in the inhibition of cyclin D1 promoter activity in MCF-7 cells. Furthermore, a positive correlation between the expression of PRMT2 and cyclin D1 was confirmed in the breast cancer tissues by using tissue microarray assay. In addition, PRMT2 was found to show a high absent percentage in breast caner cell nuclei and the nuclear loss ratio of PRMT2 was demonstrated to positively correlate with cyclin D1 expression and the increasing tumor grade of invasive ductal carcinoma. Those results offer an essential insight into the effect of PRMT2 on breast carcinogenesis, and PRMT2 nuclear loss might be an important biological marker for the diagnosis of breast cancer.
INTRODUCTION
Estrogen receptor a (ERa) is a transcription factor and engaged in a broad range of biological processes, including cell proliferation, differentiation, morphogenesis and apoptosis, [1] [2] [3] as well as the development and progression of breast cancer. 4 ERa-mediated transcription is through binding directly to specific estrogen response elements (EREs) in the promoters of responsive genes 5 or via protein-protein interaction with other promoter-bound transcription factors, such as specificity protein 1 (Sp1), 6 AP-1 7 or nuclear factor-kB. 8 In either case, coactivators or corepressors are further recruited to form a functional receptor complex that specifies transcriptional activities of downstream targets. 9 Cyclin D1 (CCND1) is a D-type cyclin that regulates G1-S cell cycle progression during cell proliferation. CCND1 is also E 2 /ERa responsive and is thought to have major roles in breast cancer. 10, 11 However, there is no classical ERE in the CCND1 promoter, and the contribution of E 2 /ERa to CCND1 action in breast cells remains unclear. 12 The roles of CCND1 transcription regulation in breast tumorigenesis need to be further defined.
Human protein arginine N-methyltransferase 2 (PRMT2, HRMT1L1) is a protein that belongs to the arginine methyltransferase family and contains a highly conserved catalytic Ado-Met-binding domain and unique Src homology 3 domain that binds proteins with proline-rich motifs. 13, 14 Initially, PRMT2 enhances ERa-mediated transactivation in CV-1 cells, 15 and subsequent research showed that PRMT2 was found to be aberrantly expressed in skeletal muscle, ovary, prostate and fetal brain, and to enhance androgen receptor-mediated transactivation dependent on the cellular background. 16 Recently, PRMT2 has been demonstrated to have weak methyltransferase activity on a histone H4 substrate, but its optimal substrates have not yet been identified. 17, 18 A series of reports show that PRMT2 is clearly involved in a variety of cellular processes, including lung function, the inflammatory response, apoptosis promotion, Wnt signaling and leptin signaling regulation, [19] [20] [21] [22] [23] suggesting that PRMT2 has diverse roles in transcriptional regulation through different mechanisms depending on its binding partners.
In previous study, we identified that PRMT2 is capable of binding to ERa both in vitro and in vivo, and we showed that PRMT2 expression was higher in human breast tumors when compared with adjacent normal tissue, suggesting a role for PRMT2 in breast tumorigenesis. 24 To further understand the physiological function of PRMT2, as well as its potential role in the development and progression of breast cancer, MCF7 breast cancer cells with high level of PRMT2 expression was used for a loss-of-function cell model by artificial microRNA (miRNA) based on the murine miR-155 sequence. 25 This study provides evidences for the negative effect of PRMT2 on breast cancer cell proliferation, uncovers the molecular mechanism of PRMT2 regulating the expression of CCND1, which accounts for PRMT2-induced proliferation suppression in breast cancer cells, and demonstrates the correlation between PRMT2 nuclear loss and grade of invasive ductal breast carcinoma. 1 
RESULTS

miRNA induced downregulation of PRMT2 expression in breast cancer cells
Initially, experiments were performed to select the best miRNA to knockdown PRMT2 expression. A pcDNA6.2-GW/EmGFP-miRbased miRNA expression plasmid with a pre-miRNA sequence was constructed and transfected to MCF7 cells. Two kinds of miRNA were designed to test their inhibitory effect on PRMT2 expression in MCF7 cells. PRMT2-miRNA1 was targeted to exon 4 of PRMT2, and PRMT2-miRNA2 was targeted to exon 9 of PRMT2 (Figure 1a) . Stable cell lines with the PRMT2-miRNAs were obtained after the transfected MCF7 cells were selected by blasticidin for 2 weeks (Supplementary Figure S1) . Immunofluorescence staining and western blotting were performed to verify the expression of PRMT2 in the transfected MCF7 cells. The cells with the pre-miRNA sequence against PRMT2 showed significantly decreased expression of PRMT2 compared with control cells with LacZ-miRNA (Figures 1b and c) . Furthermore, to evaluate knockdown of PRMT2 mRNA, real-time PCR was performed, and as shown in Figure 1d , PRMT2 mRNA levels in MCF7 cells with PRMT2-miRNAs were reduced by almost 80% and 70% respectively, as compared with those in control cells.
Suppression of PRMT2 expression promotes the cell proliferation and colony formation of MCF7 cells We next examined the effect of miRNA-induced PRMT2 downregulation on the proliferation ability of MCF7 cells. Without treatment of 17b-Estradiol (E 2 ), MCF7 cells carrying PRMT2-miRNA1, PRMT2-miRNA2 or LacZ-miRNA showed no significant difference in their growth rates at the indicated time points (Figure 2a) . Whereas, MCF7 cells with either PRMT2-miRNA1 or PRMT2-miRNA2 showed markedly increased proliferate ability compared with that of cells with LacZ-miRNA, when treated with 10 nM E 2 for 5 days (Figure 2b ). We speculated that suppression of endogenous PRMT2 expression could increase responsiveness of MCF7 cells to estrogen. To test this hypothesis, the stable MCF7 cell lines with different PRMT2 expression levels were used to determine whether the suppression of PRMT2 has any effect on the cell sensitivity to E 2 . As shown in Figure 2c , E 2 could stimulate proliferation of MCF7 cells carrying either PRMT2-miRNAs or LacZmiRNA in a dose-dependent manner, but the MCF7 with PRMT2-miRNAs present a more sensitive response to E 2 compared that with LacZ-miRNA. Meanwhile, the treatment of 4-hydroxytamoxifen could reverse the stimulate effect of E 2 on growth rates for MCF7 cells both with PRMT2-miRNAs and with LacZ-miRNA ( Figure 2d ). Colony formation assay showed that the number of formed colonies from PRMT2-miRNA1-or PRMT2-miRNA2-transfected MCF7 cells was markedly increased compared with the cells with LacZ-miRNA when treated with 10 nM E 2 , whereas, without the treatment of E 2 , the number of formed colonies of MCF7 cells carrying either PRMT2-miRNA1 or PRMT2-miRNA2 was increased slightly compared with the cells with LacZ-miRNA (Figure 2e ). Those results indicated that the effect of PRMT2 downregulation on cell proliferation is probably dependent on E 2 and E 2 could enhance the effect of PRMT2 on colony formation in MCF7 cells.
Knocking-down of PRMT2 increases tumor growth in a MCF7 xenograft mouse model To further examine the effects of PRMT2 on cell proliferation in vivo and to investigate its possible role in breast carcinogenesis, we transplanted three types of breast tumors cells developed from MCF7 cells (PRMT2-miRNA1, PRMT2-miRNA2 and LacZ-miRNA) into female nude mice. Growth of the implanted tumors was measured in mice (n ¼ 5 for each group) over a period of 8 weeks. Tumors collected from mice engrafted with MCF7-PRMT2-miRNA cells showed a reduction of PRMT2 expression compared to that with MCF7-LacZ-miRNA both at mRNA and protein levels (Figure 3a) . Knocking-down PRMT2 dramatically increased the size of tumors either engrafted with MCF7-PRMT2-miRNA1 cells or with MCF7-PRMT2-miRNA2 cells (Po0.05, Figure 3b ), but the difference between the MCF7-PRMT2-miRNA1 cells and MCF7-PRMT2-miRNA2 cells was not significant. CCND1, one of the targets of ERa was found to be upregulated in both MCF7-PRMT2-miRNA1 cells and MCF7-PRMT2-miRNA2 cells (Figure 3c ), indicating that CCND1 might be involved in the cell proliferation enhancement induced by PRMT2 knockdown. Those data suggest that knocking-down PRMT2 enhances proliferation of breast cancer cells in vivo.
Identification of PRMT2-targeting genes
To better understand the molecular mechanisms involving in the effects of PRMT2 on cell proliferation and tumorigenesis, the whole genome-wide transcriptome profile of LacZ-miRNA and PRMT2-miRNA1 cells were analyzed by Agilent oligo microarray (41 000 þ ). According to fold-change (X2.0) screening between LacZ-miRNA and PRMT2-miRNA1 cells, we found that a total of 2173 genes had altered expression, of which 795 and 1378 were upregulated and downregulated, respectively. Most of these differentially expressed genes are involved in transcription regulation, cell adhesion, immune responses, cell growth, proliferation and carcinogenesis. Forty-seven cancer-associated genes and forty-six proliferation-related genes were selected for cluster mapping on the MeV microarray analysis platform (Figures 4a and b) .
To validate the microarray data, nine upregulated genes and nine downregulated genes (Table 1) were chosen for real-time PCR confirmation. Primers for selected genes analyzed by realtime PCR are showed in Supplementary Table S1 , and as shown in Figures 4c and d, five of nine upregulated genes and eight of nine downregulated genes showed consistent alteration as microarray analysis. Interestingly, CCND1, a key modulator in cell cycle and proliferation, was found to be one of the downstream targets of PRMT2.
PRMT2 suppresses CCND1 expression in breast cancer cells Previous study showed that PRMT2 function as co-regulator of ERa in the regulation of ERa-targeting gene expression, 15 so the role of E 2 /ERa signaling in PRMT2-induced gene alterations in breast cancer cells is of worth to be investigated. To address the effect of PRMT2 on estrogen-induced ERa target genes, CCND1 and c-myc were chosen for estrogen response detection. MCF7 cells were transfected with pcDNA3.1-PRMT2 or empty vector and treated with 10 nM E 2 or ethanol vehicle for 4 h. As shown in Figures 5a and b, an average twofold increase of E 2 -induced CCND1 mRNA and protein was observed in empty vector-transfected cells and increased PRMT2 expression obviously diminished E 2 -induced CCND1 mRNA and protein expression. We also found that overexpression of PRMT2 enhanced E 2 -induced increases in c-Myc expression levels (Figures 5a and b) . These data also suggest that increased PRMT2 expression may have various effects on ERa target genes.
Having observed that increased PRMT2 expression decreased E 2 -induced CCND1 expression, it could be reasoned that PRMT2 silencing would result in an increase in the E 2 induction of CCND1. As shown in Figure 5c , PRMT2 gene expression knockdown leaded to a statistically significant (Po0.05) enhancement of E 2 -induced CCND1 protein expression levels, consistent with the results from the microarray and real-time PCR analysis. Whereas the knockdown of PRMT2 caused to a decrease of E 2 -induced c-myc expression (Figure 5c ), and the suppression of PRMT2 showed no obvious effect on the ERa expression.
PRMT2 downregulates CCND1 expression via the suppression of Akt/GSK-3b signaling in breast cancer cells It has been reported that CCND1 expression is mediated by Akt/ GSK-3b pathway, [26] [27] [28] [29] and we therefore exploited whether PRMT2 was involved in Akt/GSK-3b/CCND1 axis in MCF7 cells. First, we examined the involvement of Akt/GSK-3b signaling pathway in E 2 -induced CCND1 expression by using both LacZ-miRNA and PRMT2-miRNA MCF-7 cells. As shown in Figure 5d , pre-treatment either with wortmannin or LY294002 abrogated E 2 -induced phosphorylation of Akt and GSK-3b in MCF7 cells, resulting in obvious downregulation of CCND1 in both PRMT2-miRNA and LacZ-miRNA cells. In addition, LiCl and SB216763, two inhibitors of GSK-3b, were applied in both LacZ-miRNA and PRMT2-miRNA cells. As shown in Figure 5e , pre-treatment either with LiCl or EPCAM  CCNG2  DUSP5  ICAM5  MAPT  CCNG2  ELK1  CDK8  PRKACB  CCNF  STK4  MAPK12  CCND1  RAC2  MAP2K1  PRKX  MAP2K5  FGFR4  NF1  RPS6KA5  CCNL2  PPP5C  DUSP2  DUSP16  VEGFA  MYC  MYADM  CXCL1  VEGFB  PDCD1  RERG  S100A16  DIRAS3  CTGF  MDK  PPDPF  HDGFL1  GHRH  S100A13  GHSR  IGFBP2  GAS7  FGF6  FGF13  FGF1  S100A8   -3.0  0.0  3.0  3   BMP2  WNT10B  PIAS2  PGF  EGLN3  BIRC7  GAB1  CEBPA  ELK1  APPL1  STK4  RALBP1  SMAD2  RAC2  PTEN  LAMA4  CASP9  CDH1  RPS6KA5  FZD3  MAP2K1  EGLN1  PTEN  VEGFA  CCND1  TNFSF8  VCAN  EFEMP1  PDCD1  RERG  ICAM2  ABI3  ITGAM  MAG  BCAS3  ITGB2  ITGB8  CD2  LCN2  HLA-B  HLA-C  CNTNAP1  CLDN1  MADCAM1  ICOSLG  CLDN6  CD8B Each data point represents the mean ± s.e.m (*Po0.05, **Po0.01, ***Po0.001; statistical analyses with LacZ-miRNA group). GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
PRMT2 nuclear loss correlates with cyclin D1 overexpression J Zhong et al SB216763 also abrogated E 2 -induced phosphorylation of GSK-3b, leading to obvious downregulation of CCND1 in both PRMT2-miRNA and LacZ-miRNA cells. Those results suggested that Akt/ GSK-3b is implicated in E 2 -induced CCND1 expression in MCF-7 cells. As shown in Figures 5d and e, miRNA-mediated PRMT2 knockdown markedly increased phosphorylation of Akt and GSK3b and enhanced the expression of CCND1 with or without E 2 treatment, suggesting that the knockdown of PRMT2 could enhance Akt/GSK-3b/CCND1 signaling regardless of the presence of E 2 . The above results support the notion that PRMT2 could suppress the CCND1 expression in MCF-7 cells, at least partially via the suppression of Akt/GSK-3b signaling.
PRMT2 downregulates CCND1 expression via indirectly binding to AP-1 site of the CCND1 promoter in breast cancer cells We further explored the mechanism by which PRMT2 regulates the expression of CCND1. The promoter region containing 1980 bp upstream of the transcription start site of CCND1 was cloned and used to drive the expression of luciferase reporter in MCF7 and T47D breast cancer cells. Progressive deletions of the 5 0 end of the CCND1 promoter revealed that the À 1182-bp fragment possesses full promoter activity (Figure 6a ). Promoter motif analysis identified that an AP-1 site (TGAGTCA) locating at À 895 to À 901 bp and an ERE-like site (GGTCAAG) locating at À 779 to À 785 bp are in this obtaining promoter sequences, and those sites had been shown to be potential binding sites of ERa. Therefore, this promoter fragment was used to investigate the regulatory role of PRMT2 in its activity. As shown in Figure 6b , cotransfection of pcDNA3.1/PRMT2 greatly decreased the activity of pluc-1182 in both MCF7 and T47D cells, whereas PRMT2-miRNA1 significantly increased its basal activity, suggesting PRMT2 as a negative regulator of CCND1 promoter. Furthermore, replacing TGAGTCA with GAGACAG in the AP-1 site of pluc-1182 (luciferase plasmid at À 901 bp) abrogated the promoter's response to PRMT2 in both MCF7 and T47D cells, whereas replacing GGTCAAG with AAAAGGA in the ERE-like site of pluc-1182 (luciferase plasmid at À 785 bp) has no influence on the promoter's response to PRMT2 in both MCF7 and T47D cells (Figure 6b ). In addition, the interactions between either PRMT2 or ERa and CCND1 promoter were further confirmed by chromatin immunoprecipitation (ChIP) assay. As shown in Figure 6c , CCND1 promoter fragment containing AP-1 site was amplified by PCR assay from chromatin precipitated by either anti-PRMT2 or ERa antibody (Ab; Figure 6c , upper panel), and the knockdown PRMT2 could increase the binding affinity of ERa to CCND1 promoter ( Figure 6c , lower panel). We therefore reasoned that PRMT2 could suppress CCND1 through directly or indirectly binding to the AP-1 site of CCND1 promoter. To further validate this proposal, we tested the binding affinity of PRMT2 to the AP-1 sequence by using recombinant human full-length PRMT2 protein, and electrophoretic mobility shift assays (EMSAs) showed that recombinant PRMT2 could not directly bind to the AP-1 probe in vitro (Supplementary Figure S2) . However, a strong specific band shift with anti-PRMT2 Ab was observed in the EMSA assay with extracts from the MCF-7 cells and AP-1 probe (Figure 7) . The EMSA results demonstrated that PRMT2 bind to the AP-1 site of CCND1 promoter in an indirect manner in MCF-7 cells. Together, it could be concluded that PRMT2 suppresses the ERa-binding affinity to the AP-1 site in CCND1 promoter through indirect binding with AP-1 site, resulting in the inhibition of CCND1 promoter activity in MCF-7 cells.
PRMT2 correlates with CCND1 expression in breast carcinoma To further identify the relationship between PRMT2 and CCND1 expression in breast cancer, tissue microarray (BR1921a, US Biomax), consisting of 160 breast cancer cases and 32 normal cases, was used. The specificity of PRMT2 Ab had been tested with ectopic PRMT2 expression before the immunohistochemistry staining, and as showed in Supplementary Figure S3 . The tissue microarray analysis showed that CCND1 was stained in 39.5% of breast tumors, predominantly in nuclear with faint cytoplasmic staining, and was almost undetectable in matched normal breast tissue. As shown in Table 2 , statistical analysis confirmed that the PRMT2 and CCND1 expression were positively correlated (r ¼ 0.346, P ¼ 0.000), when analyzed regardless of breast cancer types. Furthermore, the correlation between PRMT2 and CCND1 expression was also found in invasion ductal cancer (r ¼ 0.327, P ¼ 0.003) and invasion lobular cancer (r ¼ 0.309, P ¼ 0.006), respectively. Interestingly, the level of PRMT2 in cell nuclear of breast cancer tissue was found to show obvious decrease compared with those in normal breast tissue, although the total amount of PRMT2 presented an increase in breast cancer tissue, indicating that the elevated expression of PRMT2 in breast cancer tissue might locate mainly in cytoplasm. The above results Loss of nuclear PRMT2 expression correlates with increasing tumor grade of invasive ductal carcinoma Because of the suppressive effect of PRMT2 on CCND1 expression, it could be inferred that the loss of nuclear PRMT2 expression in LacZ-miRNA or PRMT2-miRNA were cultured in steroid-deprived medium for at least 3 days, and subsequently treated with 10 nM E 2 or ethanol vehicle for 4 h. The precleared chromatin was immunoprecipitated with PRMT2 or ERa antibodies. CCND1 promoter sequence was detected by PCR with specific primers, as detailed in Materials and methods. To determine input DNA, the CCND1 promoter fragment was amplified from 5 ml purified soluble chromatin before immunoprecipitation. PCR products obtained at 35 cycles. ChIP with non-immune IgG was used as negative control. Total protein extracts were analyzed by western blot analysis for total and phosphorylated GSK-3b.
PRMT2 nuclear loss correlates with cyclin D1 overexpression J Zhong et al breast tumors would lead to an enhancement of CCND1 expression in breast cancer cells. To further confirm this hypothesis, the correlations between nuclear PRMT2 loss and CCND1 expression were analyzed by using tissue microarrays (BR1921 and BR1921a, US Biomax), and the clinicopathologic data were available in Table 3 . The immunohistochemistry analysis showed that PRMT2 protein was readily detectable in the nuclei of adjacent normal breast tissue but was absent in 64% of the tumor cell nuclei. PRMT2 immunostaining of tumor and adjacent normal tissue and the corresponding hematoxylin and eosin stains of a representative case of breast invasive ductal carcinoma are shown in Figure 8 . The percentage of tumors showing nuclear loss of PRMT2 protein is shown to be associated with the pathological types (P ¼ 0.000; Table 3 ). In invasive ductal carcinoma, the percentage of tumors showing nuclear loss of PRMT2 protein significantly increased with the progression of the tumor grade: 17% of grade 1, 62% of grade 2 and 82% of grade 3 (r ¼ 0.431, P ¼ 0.000; Table 4 ). Loss of nuclear PRMT2 expression in breast carcinoma did not show a statistically significant correlation with nodal status, metastasis, ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status of the tumor (Table 3 , P40.05). Those tissue microarray analyses strongly argued that PRMT2 protein showed a high absent percentage in tumor cell nuclei and this absent percentage of cell nuclei correlates with increasing tumor grade of invasive ductal carcinoma.
Furthermore, a positive correlation between nuclear PRMT2 loss ratio and CCND1 expression (r ¼ 0.394, P ¼ 0.000; Table 4 ) was verified in invasion ductal cancer, which is consistent with the finds that PRMT2 absent percentage in cell nuclei correlates with increasing tumor grade of invasive ductal carcinoma. In a tumor tissue overexpressing CCND1, nuclear expression of PRMT2 was not detected, whereas in the matched normal glands, the PRMT2 expression was in cell nucleic, and CCND1 protein expression was low (Figure 9a) . In another tumor tissue where PRMT2 expression was in cell nucleus, and CCND1 expression was almost undetectable (Figure 9b ). Those tissue microarray data further confirm that CCND1 is at least in part responsible for the role of PRMT2 in proliferation regulation of breast cancer cells.
DISCUSSION
Protein arginine N-methyltransferases participates in a number of cellular processes, including cell growth, 30 nuclear/cytoplasmic protein shuttling, 31 differentiation and embryogenesis, 32,33 RNA splicing and transport, 34, 35 and posttranscriptional regulation. 36 Recently, studies showed that overexpression of these enzymes are often associated with carcinogenesis and metastasis, especially in breast cancer. [37] [38] [39] [40] It has been reported that PRMT2 interacts with a number of nuclear receptors in a ligandindependent manner, and enhances nuclear receptor-mediated transactivation. 15, 16 PRMT2 directly represses E2F activity in an RBdependent manner and depletion of PRMT2 increases 
Abbreviations: CCND1, cyclin D1; PRMT2, protein arginine N-methyltransferase 2. Abbreviations: PRMT2, protein arginine N-methyltransferase 2; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
PRMT2 nuclear loss correlates with cyclin D1 overexpression J Zhong et al endogenous E2F activity and causes cells to enter S phase earlier. 41 In addition, PRMT2 can block nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IkBa) nuclear export, inhibit nuclear factor-kB transcription and promote cell apoptosis. 23 These findings suggest that PRMT2 has diverse roles in transcriptional regulation through different mechanisms.
Estrogens elicit proliferative responses in breast cancer cells through ERa-mediated transcriptional mechanisms. 42 PRMT2 has been implicated in the positive regulation of ERa-mediated gene activation in response to estrogen signaling by binding to ERa in CV-1 cells. 15 Thus, PRMT2 may be involved in the control of cell proliferation through the effect on cell cycle genes. This study provides the first evidence for the role of PRMT2 downregulation in proliferation regulation of breast cancer cells, strongly suggesting that PRMT2 function as negative modulator for the proliferation of breast cancer cells. Using the whole genome-wide transcriptome profile and real-time PCR analysis, we have shown that in breast cancer cells, miRNA-mediated RNA interference of PRMT2 affect a large body of genes expression, some of which are involved in cancer-associated genes and proliferation-related genes. CCND1, playing a critical role in G1-S phase cell cycle progression, 11, 43 was found to be one of the PRMT2 affecting downstream targets. Furthermore, we have shown that increased PRMT2 expression in MCF7 cells led to a decrease in CCND1 expression, whereas downregulation of PRMT2 expression led to an enhancement of CCND1 expression. It was observed that on the condition of E 2 , the effect of PRMT2 on CCND1 expression became more obvious. Thus, it could be inferred that the negative effect of PRMT2 on cell proliferation would be partially depended on the effect of E 2 , and other regulation mechanisms might also be involved in this process.
The CCND1 gene is a well-recognized oncogene that is overexpressed in over 50% of human mammary carcinomas. 44 Induction of CCND1 gene transcription by ERa has an important role in estrogen-mediated proliferation. 45 Although CCND1 gene transcription is directly induced by estrogen, there is no classical ERE in the CCND1 promoter. 12 Instead, the CCND1 promoter contains multiple potential estrogen-responsive sites, including an atypical cyclic AMP response element that bind c-Jun/ATF-2 proteins, 46, 47 an AP-1 sites that bind Jun/Fos 48, 49 and Sp1 sites. 50, 51 In this study, using luciferase reporter assay and ChIP PCR, we have demonstrated that downregulation of PRMT2 expression led to an increased recruitment of ERa to promoter region of AP-1 site in CCND1 promoter, and increased the promoter activity of CCND1, indicating that PRMT2 could downregulate the expression of CCND1 via suppressing the recruitment of ERa to the AP-1 site within the CCND1 promoter. Further EMSA assays showed that PRMT2 bind to AP-1 site in an indirect manner, and it could be inferred that the indirect binding of PRMT2 to AP-1 site could have a negative effect on the recruitment of ERa to the AP-1 site of CCND1 promoter, leading to the downregulation of CCND1 in MCF-7 cells. Those findings reveal a novel mechanism by which PRMT2 is involved in CCND1 expression regulation in breast cancer cells. The molecules involved in the binding of PRMT2 with AP-1 site of CCND1 promoter is of importance to unravel the accurate mechanism of PRMT2-induced CCND1 downregulation and deserves further investigation. It is well known that CCND1 overexpression is a common event in cancer and is usually a result of defective regulation at the posttranslational level. 52, 53 Therefore, regulation of the CCND1 protein level is one of the critical aspects in cell proliferation and tumor development. Previous studies have reported that CCND1 expression level is mediated by Akt/GSK-3b pathway. [27] [28] [29] It was also reported that GSK-3b could be phosphorylated and inactivated by Akt leading to an increase of CCND1 stabilization. 54 In this study, we demonstrated that miRNAmediated PRMT2 downregulation promoted CCND1 expression via activation of Akt/GSK-3b/CCND1 signaling in breast cancer cells. Thus, it could be inferred that, except for its effect on CCND1 promoter activity, PRMT2 also serve as a negative modulator of Akt/GSK-3b/CCND1 aix leading to the proliferation suppression of breast cancer cells.
The expression of PRMT2 and CCND1 was found to be positively correlated in breast cancer tissues through the analysis of tissue microarray, which seem to be inconsistent to the negative regulatory effect of PRMT2 on CCND1 expression. Further analysis to the tissue microarray data unraveled a fact that the level of Abbreviations: CCDN1, cyclin D1; PRMT2, protein arginine N-methyltransferase 2.
PRMT2 nuclear loss correlates with cyclin D1 overexpression J Zhong et al PRMT2 in cell nucleus of breast cancer tissue showed obvious decrease compared with those in normal breast tissue, although the total amount of PRMT2 presented an increase in breast cancer tissue, indicating that the elevated expression of PRMT2 in breast cancer tissue might locate mainly in cytoplasm. Furthermore, a positive correlation between nuclear PRMT2 loss ratio and CCND1 expression in invasion ductal cancer was verified, which is consistent with the results from luciferase and ChIP assays in cells models, suggesting that loss of PRMT2 may be of importance in deregulating CCND1 expression in human breast cancer. Further analysis identify that the PRMT2 absent percentage of cell nucleus correlates with increasing tumor grade of invasive ductal carcinoma, and this phenomenon was also observed in the investigation on the role of BTG2 in breast cancer progression, in which the loss of nuclear BTG2 expression in ERa-positive breast tumors was showed to be correlated significantly with increased histologic grade and tumor size. 55 The mechanism by which PRMT2 nuclear transportation is blocked during breast carcinogenesis remains elusive, and the clarification of associated molecular events would be helpful for understanding the role of PRMT2 cytoplasm accumulation in the progress of breast cancer.
To our knowledge, this is the first report for the role of PRMT2 in proliferation regulation of breast cancer cells. The present work provides evidences for the underling mechanism by which PRMT2 negatively regultes the expression of CCND1 in breast cancer cells, and both genomic effect and non-genomic effect of PRMT2 were found to be involved in the regulation of CCND1 expression. Furthermore, it was found that the absent percentage of PRMT2 in cell nuclei correlates with increasing tumor grade of invasive ductal carcinoma. Those results provide an essential insight into the effect of PRMT2 on carcinogenesis of breast tumor, rending PRMT2 to be important biological marker for the diagnosis of breast cancer.
MATERIALS AND METHODS
Cell culture MCF7 and T47D were cultured as described previously. 24 
Design of artificial miRNAs and transfection
We designed the PRMT2-targeting sequence, PRMT2-miRNA1 was targeted to exon 4 and PRMT2-miRNA2 was targeted to exon 9 ( Figure 1a) . These miRNA gene double strands were ligated and cloned into the pcDNA6.2GW/EmGFP vector (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Then, the vectors were transfected into the MCF7 cells using Lipofectamine2000 (Invitrogen) according to the manufacturer's instruction.
Western blot analysis Transient transfection and luciferase activity assay Transient gene delivery was carried out to assess the effect of PRMT2 on CCND1 promoter activity in MCF7 and T47D cells as described previously. 24 A luciferase assay kit (Promega) was used to measure the reporter activity according to the manufacturer's instructions. Luciferase activity was normalized by using a Renilla luciferase internal control.
Site-directed mutagenesis
Mutants (pLuc-901m and pLuc-785m) of CCND1 promoter were generated using a QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The TGAGTCA sequence in the binding site of AP-1 was replaced by GAGACAG, the GGTCAAG sequence in the ERE-like site was replaced by AAAAGGA, and confirmed by sequencing.
ChIP assay MCF7 cells were fixed by the addition of 1% formaldehyde to the medium for 10 min. Formaldehyde was quenched by the addition of 1 Â glycine for 5 min at room temperature. A ChIP assay was performed as described previously 56 with 5 ml of immunoprecipitated DNA and primers (forward 5 0 -AGGTGAAGGGACGTCTAC-3 0 and reverse 5 0 -TAGCCTGGAGACTCTTCG-3 0 ) located at À 1019 to À 1002 bp and À 764 to À 747 bp of the CCND1 promoter.
Tissue microarray and immunohistochemical analysis
Two tissue microarrays (BR1921 and BR1921a, US Biomax, Rockville, MD, USA) were used, and each of them consists of 160 breast cancer cases and 32 normal cases, respectively, and were histologically interpretable and analyzed for the correlation with clinicopathological parameters. Immunohistochemistry staining was performed as detailed in our previous studies. 24 The rabbit polyclonal PRMT2 (1:50; Aviva Systems Biology, Beijing, China) and CCND1 Ab (1:10; Cell Signaling Technology) were used.
Additional assays and methods
Cell growth and colony formation assay, global cDNA microarray analysis, real-time PCR, mouse tumour xenografts experiments and EMSAs are described in Supplementary Materials and methods.
Statistical analysis
All experiments were performed with three replicates and the results were expressed as the mean ± s.e.m. or mean ± s.d. Statistical analysis was done using SPSS, version 13.0 (SPSS, Inc., Chicago, IL, USA). A statistical association between clinicopathological and molecular parameters was tested, using non-parametrically two-tailed Mann-Whitney U-test. P values o0.05 were considered significant. Spearman's rank-correlation coefficients were used to assess the relationship between PRMT2 and CCND1 expression.
